Avenue Therapeutics (ATXI) Competitors $0.33 +0.02 (+5.91%) As of 08/7/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. TCRT, INM, ALBT, MTNB, GLTO, ADIL, DRMA, CMND, INDP, and JAGXShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Alaunos Therapeutics (TCRT), InMed Pharmaceuticals (INM), Avalon GloboCare (ALBT), Matinas Biopharma (MTNB), Galecto (GLTO), Adial Pharmaceuticals (ADIL), Dermata Therapeutics (DRMA), Clearmind Medicine (CMND), Indaptus Therapeutics (INDP), and Jaguar Animal Health (JAGX). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors Alaunos Therapeutics InMed Pharmaceuticals Avalon GloboCare Matinas Biopharma Galecto Adial Pharmaceuticals Dermata Therapeutics Clearmind Medicine Indaptus Therapeutics Jaguar Animal Health Alaunos Therapeutics (NASDAQ:TCRT) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment. Is TCRT or ATXI more profitable? Alaunos Therapeutics' return on equity of -169.34% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -169.34% -124.28% Avenue Therapeutics N/A -471.57%-296.50% Which has preferable valuation and earnings, TCRT or ATXI? Alaunos Therapeutics has higher revenue and earnings than Avenue Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos Therapeutics$11K414.47-$4.68M-$2.54-1.09Avenue TherapeuticsN/AN/A-$10.38M-$7.49-0.04 Does the media refer more to TCRT or ATXI? In the previous week, Alaunos Therapeutics' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score. Company Overall Sentiment Alaunos Therapeutics Neutral Avenue Therapeutics Neutral Do institutionals and insiders hold more shares of TCRT or ATXI? 27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryAlaunos Therapeutics beats Avenue Therapeutics on 7 of the 8 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.05M$785.27M$5.42B$9.56BDividend YieldN/A4.84%3.99%4.14%P/E Ratio0.021.2929.9025.14Price / SalesN/A25.43372.1776.15Price / CashN/A19.5635.9458.58Price / Book0.176.578.105.59Net Income-$10.38M-$3.92M$3.26B$265.48M7 Day Performance-28.26%-2.83%0.65%1.22%1 Month Performance41.45%-0.30%2.43%0.39%1 Year Performance-85.90%23.98%27.70%23.47% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics2.3596 of 5 stars$0.33+5.9%N/A-85.9%$1.05MN/A0.024Gap UpTCRTAlaunos Therapeutics0.5095 of 5 stars$2.85-5.8%N/A+2.8%$4.67M$11K-1.1240Upcoming EarningsINMInMed Pharmaceuticals0.0754 of 5 stars$2.31-2.5%N/A-16.0%$4.62M$4.60M-0.1910ALBTAvalon GloboCare0.9704 of 5 stars$2.38+5.3%N/A-42.2%$4.50M$1.37M-0.125MTNBMatinas Biopharma0.6009 of 5 stars$0.88-8.6%N/AN/A$4.45MN/A-0.1830Gap UpGLTOGalecto2.9079 of 5 stars$3.33-1.8%$10.00+200.3%-72.8%$4.40MN/A-0.2140Positive NewsEarnings ReportUpcoming EarningsGap UpADILAdial Pharmaceuticals2.8399 of 5 stars$0.43+2.6%$8.00+1,777.9%-61.0%$4.36MN/A-0.2920Upcoming EarningsGap UpDRMADermata Therapeutics1.7152 of 5 stars$6.80-3.7%$30.00+341.2%-72.7%$4.36MN/A-0.428Negative NewsShort Interest ↑CMNDClearmind Medicine0.3171 of 5 stars$0.99+0.7%N/A-20.9%$4.21MN/A-0.90N/ANews CoverageGap UpINDPIndaptus Therapeutics2.942 of 5 stars$7.26-0.5%$238.00+3,178.2%-85.6%$4.14MN/A-0.176Upcoming EarningsJAGXJaguar Animal Health1.8326 of 5 stars$2.17+0.8%$60.00+2,667.5%-92.1%$4.12M$11.69M0.0050Negative NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies Alaunos Therapeutics Alternatives InMed Pharmaceuticals Alternatives Avalon GloboCare Alternatives Matinas Biopharma Alternatives Galecto Alternatives Adial Pharmaceuticals Alternatives Dermata Therapeutics Alternatives Clearmind Medicine Alternatives Indaptus Therapeutics Alternatives Jaguar Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXI Stock Alerts